Eyam Health

Eyam Health is a biotechnology enterprise specializing in the rapid design and scalable delivery of biologic medicines through its dual-platform approach, combining AI-powered payload design (Jennerator) with a self-amplifying nucleic acid system (Gemini). The company addresses the critical challenges of lengthy development timelines, high manufacturing costs, and cold-chain dependencies that limit traditional vaccine, antibody, and gene therapy products. Its platform has demonstrated the ability to shorten design cycles from months to days and validated durable in vivo expression, as evidenced by collaborative studies with the Gates Foundation.